Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Nicole F Liachko | Pamela J McMillan | Timothy J Strovas | Elaine Loomis | Lynne Greenup | Jill R Murrell | Bernardino Ghetti | Murray A Raskind | Thomas J Montine | Thomas D Bird | James B Leverenz | Brian C Kraemer
PLoS genetics | 2014

Pathological aggregates of phosphorylated TDP-43 characterize amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), two devastating groups of neurodegenerative disease. Kinase hyperactivity may be a consistent feature of ALS and FTLD-TDP, as phosphorylated TDP-43 is not observed in the absence of neurodegeneration. By examining changes in TDP-43 phosphorylation state, we have identified kinases controlling TDP-43 phosphorylation in a C. elegans model of ALS. In this kinome-wide survey, we identified homologs of the tau tubulin kinases 1 and 2 (TTBK1 and TTBK2), which were also identified in a prior screen for kinase modifiers of TDP-43 behavioral phenotypes. Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells. TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states. Furthermore, protein levels of TTBK1 and TTBK2 are increased in frontal cortex of FTLD-TDP patients, and TTBK1 and TTBK2 co-localize with TDP-43 inclusions in ALS spinal cord. These kinases may represent attractive targets for therapeutic intervention for TDP-43 proteinopathies such as ALS and FTLD-TDP.

Pubmed ID: 25473830

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: 5P50NS2062684-02
  • Agency: NIA NIH HHS, United States
    Id: P01 AG017586
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS064131
  • Agency: NIA NIH HHS, United States
    Id: P50 AG005136
  • Agency: NIA NIH HHS, United States
    Id: 2P50AG005136-27
  • Agency: NINDS NIH HHS, United States
    Id: R01NS064131
  • Agency: CSRD VA, United States
    Id: I01 CX001006
  • Agency: BLRD VA, United States
    Id: IK2 BX002243
  • Agency: BLRD VA, United States
    Id: I01 BX002619
  • Agency: NIA NIH HHS, United States
    Id: T32 AG000057
  • Agency: NIA NIH HHS, United States
    Id: AG 000057-31

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NSC-34 (tool)

RRID:CVCL_D356

Cell line NSC-34 is a Hybrid cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

SH-SY5Y (tool)

RRID:CVCL_0019

Cell line SH-SY5Y is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions